Expertise in
3
conditions

Kwang-yu Chang

Tainan, TNQ, TW 
Expertise in
3
conditions
Tainan, TNQ, TW 

Overview

Kwang-yu Chang practices practicing medicine in Tainan, Taiwan.

Chang is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

They are actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 4 clinical trials.

Locations

Tainan, TNQ 70456, Taiwan
Other Locations
Miaoli, TNQ, Taiwan
Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study): a Single-arm, Phase II Study
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study): a Single-arm, Phase II Study
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: BI-754091, Afatinib
Study Phase: Phase 2
Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI, PEP02, MM-398, Onivyde®) With 5-FU and Leucovorin in Squamous Cell Carcinoma (SCC) of Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI, PEP02, MM-398, Onivyde®) With 5-FU and Leucovorin in Squamous Cell Carcinoma (SCC) of Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
Enrollment Status: Completed
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Irinotecan, 5-FU, Leucovorin
Study Phase: Phase 2
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
View 3 Less Clinical Trials

51 Total Publications

KDM1A/HDAC2-driven epigenetic dysregulation maintains a drug-resistant, relapse-initiating glioblastoma cell niche at the peri-tumoral margin.
KDM1A/HDAC2-driven epigenetic dysregulation maintains a drug-resistant, relapse-initiating glioblastoma cell niche at the peri-tumoral margin.
Journal: Biochemical pharmacology
Published: February 23, 2026

Frequently Asked Questions about Kwang-yu Chang

Is Kwang-yu Chang a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Kwang-yu Chang is classified as an Advanced expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kwang-yu Chang participate in research or clinical trials?

Yes. Kwang-yu Chang has published 51 articles and abstracts on conditions like Glioblastoma. You can view a list of Kwang-yu Chang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chang's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile